![](https://www.diabetesnews.com/wp-content/uploads/2013/06/Insulin-645x250-150x150.jpg)
There is no evidence that patients with diabetes who initiate insulin glargine have a higher risk of cancer than similar patients initiating human neutral protamine Hagedorn (NPH) insulin, according to a study published online July 22 in Diabetes Care.
Read more